Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report

Monoclonal antibodies blocking PD-1 and CTLA-4 immunological checkpoints lead to durable tumor responses in a considerable number of advanced melanoma patients. Besides their anti-neoplastic efficacy, these immune checkpoint inhibitors cause a wide range of immune-related adverse events (irAEs), oft...

Descripción completa

Detalles Bibliográficos
Autores principales: Matull, Johanna, Livingstone, Elisabeth, Wetter, Axel, Zimmer, Lisa, Zaremba, Anne, Lahner, Harald, Schadendorf, Dirk, Ugurel, Selma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686558/
https://www.ncbi.nlm.nih.gov/pubmed/33262949
http://dx.doi.org/10.3389/fonc.2020.592609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686558/
https://www.ncbi.nlm.nih.gov/pubmed/33262949
http://dx.doi.org/10.3389/fonc.2020.592609

Ejemplares similares